An Observational Study Evaluating SYMLIN® (pramlintide acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Exclusion Criteria

• - The following exclusion criteria are consistent with the SYMLIN package insert and specifically exclude patients who:
• · Are poorly compliant with their current insulin regimen, as defined by their HCP
• · Are poorly compliant with prescribed blood glucose self monitoring, as defined by their HCP
• · Have experienced recurrent patient-ascertained severe hypoglycemia requiring assistance during the past 6 months
• · Have hypoglycemia unawareness
• · Have a confirmed diagnosis of gastroparesis
• · Require the use of drugs that stimulate gastrointestinal motility
• · Are female and pregnant or lactating and for whom the HCP determines the potential benefit does not justify the potential risk to the fetus or infant
• · Have been treated with SYMLIN within 3 months prior to study start